Treatment of primary first-episode genital herpes simplex virus infections with acyclovir

Results of topical, intravenous and oral therapy

L. Corey, J. Benedetti, C. Critchlow, G. Mertz, J. Douglas, Kenneth Fife, A. Fahnlander, M. L. Remington, C. Winter, J. Dragavon

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Three double-blind, placebo-controlled evaluations of acyclovir were performed in first-episode genital herpes infections. In one trial intravenous acyclovir or saline was administered in hospital over 5 days. In the other two trials, 10-day courses of oral, or 7-day courses of topical acyclovir and respective placebos were followed up in the outpatient department. Regular assessments included staging examinations, culture of lesions and blood and serum analyses. No patient discontinued medication because of an adverse reaction, although one quarter of topically treated patients complained of local irritation on application. The placebo-controlled evaluations indicate that, if given within the first 7 days after the onset of lesions, topical, intravenous and oral acyclovir are useful in shortening the course of first-episode primary genital herpes. The clinical and virological effects of intravenous and oral acyclovir were more marked than those of topical treatment in the reduction of viral shedding; the time to complete healing of lesions; and in the reduction of new lesion formation. Systemic preparations of acyclovir also decreased the symptoms of herpes simplex virus urethritis and intravenous acyclovir those of herpes simplex virus cervicitis. Neither systemic treatment, however, was effective in delaying or reducing the frequency of subsequent recurrences, which may be related to the development of early ganglionic infection. Despite this, acyclovir treatment is a significant advance in the management of primary genital herpes.

Original languageEnglish (US)
Pages (from-to)79-88
Number of pages10
JournalJournal of Antimicrobial Chemotherapy
Volume12
Issue numberSUPPL. B
StatePublished - 1983
Externally publishedYes

Fingerprint

Herpes Genitalis
Acyclovir
Placebos
Simplexvirus
Therapeutics
Uterine Cervicitis
Virus Shedding
Urethritis
Infection
Outpatients
Recurrence

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

Treatment of primary first-episode genital herpes simplex virus infections with acyclovir : Results of topical, intravenous and oral therapy. / Corey, L.; Benedetti, J.; Critchlow, C.; Mertz, G.; Douglas, J.; Fife, Kenneth; Fahnlander, A.; Remington, M. L.; Winter, C.; Dragavon, J.

In: Journal of Antimicrobial Chemotherapy, Vol. 12, No. SUPPL. B, 1983, p. 79-88.

Research output: Contribution to journalArticle

Corey, L, Benedetti, J, Critchlow, C, Mertz, G, Douglas, J, Fife, K, Fahnlander, A, Remington, ML, Winter, C & Dragavon, J 1983, 'Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: Results of topical, intravenous and oral therapy', Journal of Antimicrobial Chemotherapy, vol. 12, no. SUPPL. B, pp. 79-88.
Corey, L. ; Benedetti, J. ; Critchlow, C. ; Mertz, G. ; Douglas, J. ; Fife, Kenneth ; Fahnlander, A. ; Remington, M. L. ; Winter, C. ; Dragavon, J. / Treatment of primary first-episode genital herpes simplex virus infections with acyclovir : Results of topical, intravenous and oral therapy. In: Journal of Antimicrobial Chemotherapy. 1983 ; Vol. 12, No. SUPPL. B. pp. 79-88.
@article{095233f477424337b8220417aeecf4ea,
title = "Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: Results of topical, intravenous and oral therapy",
abstract = "Three double-blind, placebo-controlled evaluations of acyclovir were performed in first-episode genital herpes infections. In one trial intravenous acyclovir or saline was administered in hospital over 5 days. In the other two trials, 10-day courses of oral, or 7-day courses of topical acyclovir and respective placebos were followed up in the outpatient department. Regular assessments included staging examinations, culture of lesions and blood and serum analyses. No patient discontinued medication because of an adverse reaction, although one quarter of topically treated patients complained of local irritation on application. The placebo-controlled evaluations indicate that, if given within the first 7 days after the onset of lesions, topical, intravenous and oral acyclovir are useful in shortening the course of first-episode primary genital herpes. The clinical and virological effects of intravenous and oral acyclovir were more marked than those of topical treatment in the reduction of viral shedding; the time to complete healing of lesions; and in the reduction of new lesion formation. Systemic preparations of acyclovir also decreased the symptoms of herpes simplex virus urethritis and intravenous acyclovir those of herpes simplex virus cervicitis. Neither systemic treatment, however, was effective in delaying or reducing the frequency of subsequent recurrences, which may be related to the development of early ganglionic infection. Despite this, acyclovir treatment is a significant advance in the management of primary genital herpes.",
author = "L. Corey and J. Benedetti and C. Critchlow and G. Mertz and J. Douglas and Kenneth Fife and A. Fahnlander and Remington, {M. L.} and C. Winter and J. Dragavon",
year = "1983",
language = "English (US)",
volume = "12",
pages = "79--88",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "SUPPL. B",

}

TY - JOUR

T1 - Treatment of primary first-episode genital herpes simplex virus infections with acyclovir

T2 - Results of topical, intravenous and oral therapy

AU - Corey, L.

AU - Benedetti, J.

AU - Critchlow, C.

AU - Mertz, G.

AU - Douglas, J.

AU - Fife, Kenneth

AU - Fahnlander, A.

AU - Remington, M. L.

AU - Winter, C.

AU - Dragavon, J.

PY - 1983

Y1 - 1983

N2 - Three double-blind, placebo-controlled evaluations of acyclovir were performed in first-episode genital herpes infections. In one trial intravenous acyclovir or saline was administered in hospital over 5 days. In the other two trials, 10-day courses of oral, or 7-day courses of topical acyclovir and respective placebos were followed up in the outpatient department. Regular assessments included staging examinations, culture of lesions and blood and serum analyses. No patient discontinued medication because of an adverse reaction, although one quarter of topically treated patients complained of local irritation on application. The placebo-controlled evaluations indicate that, if given within the first 7 days after the onset of lesions, topical, intravenous and oral acyclovir are useful in shortening the course of first-episode primary genital herpes. The clinical and virological effects of intravenous and oral acyclovir were more marked than those of topical treatment in the reduction of viral shedding; the time to complete healing of lesions; and in the reduction of new lesion formation. Systemic preparations of acyclovir also decreased the symptoms of herpes simplex virus urethritis and intravenous acyclovir those of herpes simplex virus cervicitis. Neither systemic treatment, however, was effective in delaying or reducing the frequency of subsequent recurrences, which may be related to the development of early ganglionic infection. Despite this, acyclovir treatment is a significant advance in the management of primary genital herpes.

AB - Three double-blind, placebo-controlled evaluations of acyclovir were performed in first-episode genital herpes infections. In one trial intravenous acyclovir or saline was administered in hospital over 5 days. In the other two trials, 10-day courses of oral, or 7-day courses of topical acyclovir and respective placebos were followed up in the outpatient department. Regular assessments included staging examinations, culture of lesions and blood and serum analyses. No patient discontinued medication because of an adverse reaction, although one quarter of topically treated patients complained of local irritation on application. The placebo-controlled evaluations indicate that, if given within the first 7 days after the onset of lesions, topical, intravenous and oral acyclovir are useful in shortening the course of first-episode primary genital herpes. The clinical and virological effects of intravenous and oral acyclovir were more marked than those of topical treatment in the reduction of viral shedding; the time to complete healing of lesions; and in the reduction of new lesion formation. Systemic preparations of acyclovir also decreased the symptoms of herpes simplex virus urethritis and intravenous acyclovir those of herpes simplex virus cervicitis. Neither systemic treatment, however, was effective in delaying or reducing the frequency of subsequent recurrences, which may be related to the development of early ganglionic infection. Despite this, acyclovir treatment is a significant advance in the management of primary genital herpes.

UR - http://www.scopus.com/inward/record.url?scp=0021083645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021083645&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 79

EP - 88

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - SUPPL. B

ER -